Stereotaxis expects annual revenue to surpass $40M with Q3 and Q4 above $10M as MAGiC and Synchrony ramp

Earnings Call Insights: Stereotaxis, Inc. (STXS) Q1 2026

MANAGEMENT VIEW

* "Stereotaxis has had an amazing start to this year" and management framed Q1 as a period where "our reported quarterly numbers don't yet reflect it," while citing "the initial commercial green shoots of success" and "clarity on the opportunity ahead of us" (CEO & Chairman David Fischel).
* "In just the past few months, we received 4 U.S. FDA regulatory approvals for a complex surgical robot, robotically steered therapeutic and diagnostic catheters and a digital surgery cockpit" and the company said MAGiC "strategically allows us to overcome our historical dependency on Johnson & Johnson" while participating "robustly in the recurring revenue of each procedure" (CEO & Chairman Fischel).
* "Demand for MAGiC is much higher than supply" and the company said its contract manufacturer "still expects production to top 500 catheters a month by the end of this year," while also stating, "to mitigate catheter shortages, we began selling an additional catheter in Europe" via MicroPort and are pursuing "other efforts that expand production capacity and redundancy" (CEO & Chairman Fischel).
* "We have already received orders for multiple systems and have shipped the first systems to customers" for Synchrony, and management said, "We are very confident in our guidance of $3 million in revenue from Synchrony this year" (CEO & Chairman Fischel).
* "Revenue for the first quarter of 2026 totaled $6.3 million" with "system revenue of $1.3 million" and "recurring revenue of $5 million," and the company said recurring revenue "was pressured by the transition from the Johnson & Johnson ecosystem" (Chief Financial Officer Kimberly Peery).

OUTLOOK

* "We are reiterating our revenue guidance for the year of double-digit revenue growth, with annual revenue expected to surpass $40 million" and management added, "Revenue will ramp up sequentially each quarter, and we expect both the third and fourth quarters of this year to have revenue of above $10 million a quarter" (CEO & Chairman Fischel).
* On financing and dilution, management said it is "confident that we can advance our strategy, integrate Robocath, and grow significantly without subjecting investors to substantial dilution" and added it "opportunistically taken advantage of the ATM" with "overall minimal dilution" while also pursuing "strategic opportunities for non-dilutive non-debt financing" (CEO & Chairman Fischel).
* Versus the prior call’s framing of the first half/second half shape, the company again emphasized a back-half ramp; previously, management said, "We expect quarterly revenue to be below $10 million per quarter in the first 2 quarters of the year and then to ramp above $10 million" in the last two quarters (CEO & Chairman Fischel, Q4 2025).

FINANCIAL RESULTS

* "Revenue for the first quarter of 2026 totaled $6.3 million compared to $7.5 million in the prior year's first quarter" (Chief Financial Officer Peery).
* "Gross margin for the first quarter of 2026 was 60% of revenue" including "recurring revenue gross margin was 66%, and system gross margin was 39%" (Chief Financial Officer Peery).
* "Operating loss and net loss in the first quarter of 2026 were $6 million and $5.9 million" and "negative free cash flow for the first quarter was $3.5 million" (Chief Financial Officer Peery).
* "At March 31, Stereotaxis had cash and cash equivalents of $14.6 million and no debt" (Chief Financial Officer Peery).

Q&A

* Daniel Stauder, Citizens JMP Securities, LLC, Research Division: asked about MAGiC utilization stickiness and ramp; CEO Fischel: "MAGiC adoption is right now still limited by production capacity" and described three customer "buckets" ranging from wanting to "transition 100% over" to staying with J&J "as long as they can," adding, "it's a ground game account by account."
* Stauder, Citizens JMP Securities, LLC, Research Division: asked what underpins the "$40 million plus" plan and manufacturing improvement timing; CEO Fischel: pointed to "500 catheters a month by the end of this year" and said, "you can do kind of back of envelope math" that implies disposables becoming "higher than all of our recurring revenue right now," while noting Q1 was "a particularly weak quarter from a system perspective."
* Kyle Edward Winborne, Piper Sandler & Co., Research Division: asked to quantify disposable impact in Q1; CEO Fischel: "MAGiC and MAGiC Sweep... was very small in the quarter overall" and said "very little revenue recognition in the first quarter" as January/February output was used to "improv[e] the yield significantly," while "the primary headwind is that Johnson & Johnson has not been supplying catheters well to accounts."
* Winborne, Piper Sandler & Co., Research Division: asked about GenesisX discussions and timing; CEO Fischel: said GenesisX compatibility with "non-integrated x-rays" is "a structural change" and the near-term focus is "proving the model" with early accounts that accept first-mover risk, adding, "we're glad that we do have accounts" to serve as "show places."
* Joshua Jennings, TD Cowen, Research Division: asked about J&J turbulence, mapping platforms, and Carto; CEO Fischel: said MAGiC is predominantly used with "Abbott's EnSite X" and added, "There are some ways to make MAGiC work also with Carto," while also citing MicroPort Columbus outside the U.S.
* Jennings, TD Cowen, Research Division: asked about PFA progress and ASC opportunity; CEO Fischel: said CardioFocus compatibility work is "clearly underway" with "regulatory engagement with a notified body" and added that catheter "stability... [is] particularly important for PFA," while for ASCs, "we think that our robot can provide a big benefit" and "hope, believe that one of those GenesisX installations this year will be in the ASC setting."

SENTIMENT ANALYSIS

* Analyst tone was neutral to slightly positive, leaning into diligence on execution risk, with questions repeatedly probing manufacturing constraints, the J&J transition, and the visibility behind the "$40 million plus" plan.
* Management tone was slightly positive in prepared remarks and more operationally candid in Q&A, repeatedly emphasizing constraints and transition friction, including "MAGiC adoption is right now still limited by production capacity" and "This transition is messy" (CEO & Chairman Fischel).
* Versus the prior quarter, management maintained an optimistic innovation narrative but sounded more direct about near-term headwinds, while still reiterating the same back-half ramp language on quarterly revenue (CEO & Chairman Fischel, Q1 2026; CEO & Chairman Fischel, Q4 2025).

QUARTER-OVER-QUARTER COMPARISON

* Management’s core guidance structure remained consistent: in Q1 2026 it reiterated "annual revenue expected to surpass $40 million" and "both the third and fourth quarters... above $10 million" (CEO & Chairman Fischel), aligning with Q4 2025’s expectation of "below $10 million" in the first half and "above $10 million" in the second half (CEO & Chairman Fischel, Q4 2025).
* Strategic focus expanded from the prior quarter’s emphasis on four commercialization pillars to integrating M&A, with Q1 highlighting, "we announced the acquisition of Robocath last month" as a step toward a broader endovascular robotics vision (CEO & Chairman Fischel).
* Analysts shifted from earlier-year commercialization mechanics (e.g., GenesisX program goals and Synchrony clearance timing in Q4) toward pressure-testing Q1 execution bottlenecks, particularly catheter supply, J&J disruption, and practical cadence of procedure conversion.

RISKS AND CONCERNS

* Management identified transition and supply risk: "Demand for MAGiC is much higher than supply" and "This transition is messy" as the company winds down reliance on Johnson & Johnson (CEO & Chairman Fischel).
* Manufacturing ramp timing remained a key dependency, with production intended to "top 500 catheters a month by the end of this year" and management describing the ramp as "gradual" with "operational and commercial friction" (CEO & Chairman Fischel).
* Liquidity and cash use were indirectly addressed via balance sheet comments, including "no debt" and the stated intent to avoid "substantial dilution" while using the ATM and pursuing "non-dilutive non-debt financing" (CEO & Chairman Fischel; Chief Financial Officer Peery).

FINAL TAKEAWAY

Management presented Q1 as a low-revenue quarter that did not reflect what it called early commercial traction from newly approved products, while reiterating a 2026 plan for double-digit growth and annual revenue expected to surpass $40 million with Q3 and Q4 above $10 million per quarter. The call centered on execution factors that management said will determine timing—MAGiC supply ramp and the Johnson & Johnson transition—alongside initial Synchrony shipments and orders and the integration pathway for the Robocath acquisition.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/stxs/earnings/transcripts]

MORE ON STEREOTAXIS

* Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4903527-stereotaxis-inc-stxs-q1-2026-earnings-call-transcript]
* Stereotaxis, Inc. (STXS) M&A Call Transcript [https://seekingalpha.com/article/4890929-stereotaxis-inc-stxs-m-and-a-call-transcript]
* Stereotaxis: Medical Robotics Upside Offsets Cash Burn And Execution Risks [https://seekingalpha.com/article/4882136-stereotaxis-medical-robotics-upside-offsets-cash-burn-and-execution-risks]
* Stereotaxis GAAP EPS of -$0.06 misses by $0.01, revenue of $6.2M misses by $2.3M [https://seekingalpha.com/news/4591588-stereotaxis-gaap-eps-of-0_06-misses-by-0_01-revenue-of-6_2m-misses-by-2_3m]
* Stereotaxis Q1 2026 Earnings Preview [https://seekingalpha.com/news/4590605-stereotaxis-q1-2026-earnings-preview]